A single high-dose cycle of chemotherapy can produce response rates in excess of 50%. However, disease-free survival ( /day ؋ 4) (CTCb). Sixty-one women were enrolled and 60 completed all three cycles. Following the paclitaxel infusion most patients developed a reversible, predominantly sensory polyneuropathy. Of the 30 patients with measurable disease, 12 converted to CR, nine converted to a PR*, and five had a further PR, giving an overall response rate of 87%. The toxic death rate was 5%. No patient progressed on study. Thirty percent are progression-free with a median follow-up of 31 months (range 1-43 months) and overall survival is 61%. Three sequential high-dose cycles of chemotherapy are feasible and resulted in a high response rate. The challenge continues to be maintenance of response and provides the opportunity to evaluate strategies for eliminating minimal residual disease.
Advanced breast cancer continues to be a highly treatable, albeit ultimately deadly disease, with a median survival of 2 to 2.5 years. 1 New cytotoxics and biologics may lengthen survival in the order of 1 to 5 months. However, long-term disease-free survival is rare. [2] [3] [4] The research interest in very high-dose chemotherapy sprang from the observation of a linear-log relationship between dose and tumor cell kill. Early clinical studies determined that 15 to 20% of women who achieved a complete response as a consequence of a single high-dose cycle of chemotherapy as consolidation for responding metastatic breast cancer maintained this response for longer than 5 years -in contrast to less than 5% observed in previous studies. 2 However, that the observation of improved survival might be due to selection bias is suggested in a retrospective review of a large database. 5 There are five randomized trials assessing high-dose chemotherapy with autologous stem cell support as a component of overall therapy in patients with metastatic breast cancer. Two of these trials demonstrate equivalence of a single high-dose cycle of chemotherapy with stem cell support to maintenance chemotherapy. 6, 7 Survival was doubled in the small French trial, a difference that was not statistically significant. 8 The two Duke University trials compare a single high-dose cycle of chemotherapy after four cycles of conventional therapy vs observation alone, with the high-dose therapy producing superior disease-free survival. 9, 10 Patients with relapse on the conventional dose arm in these two Duke studies were then crossed over to high-dose therapy, obviating the survival comparison of conventional versus high-dose therapy.
Several arguments favor evaluation of sequential highdose chemotherapy as compared to a single high-dose cycle. First, curative chemotherapy regimens for testis, lymphoma and breast cancer in the adjuvant setting require repetitive chemotherapy cycles. Second, the North American Autologous Bone Marrow Transplant Registry (ABMTR) data suggest that a complete response is associated with a higher probability of remaining progression-free than are a partial or non-response. 11 The goal of this trial of sequential high-dose chemotherapy was to attempt to increase the complete response rate to determine if an increased proportion of patients would remain disease-free.
Paclitaxel is one of the more active agents against breast cancer to emerge in the past 20 years. Pre-clinical data in breast cancer cell lines and MDA-4 transplanted tumors in C3Hf/Kam mice support a dose-concentration/response effect in breast cancer. 12, 13 In the standard dose range, a modest improvement in response rate was observed after increasing the dose from 135 mg/m 2 to 175 mg/m 2 although dose-limiting myelosuppression and neuropathy precluded further escalation in dose and assessment of a doseresponse. 14 Our group has conducted a series of tandem transplant trials for women with responsive advanced breast cancer. Our phase I trial of three separate high-dose cycles of chemotherapy with stem cell support consisted of doseescalating paclitaxel followed by melphalan followed by CTCb (cyclophosphamide, thiotepa, carboplatin). The rationale for the melphalan and CTCb backbone derived from data generated by Ayash and colleagues, 15 in which this tandem transplant was superior in terms of response and disease-free survival at 2 years of follow-up as compared to prior experience with CTCb alone. In our phase I trial of a dose escalation of paclitaxel as the first high-dose cycle of a tandem high-dose chemotherapy regimen, we reported an overall response rate of 79%. 16 At a median follow-up of 60 months, 30% are disease-free and 45% are alive.
Materials and methods

Patient eligibility
Women aged 18 to 60 years with responding (complete or partial response) histologically-documented stage 4 breast cancer were eligible if hepatic (bilirubin р2 times normal, SGOT р1.5 times normal), renal (creatinine Ͻ1.5 times normal) and cardiac (left ventricular ejection fraction у45%) functions and performance status (ECOG 0-1) were adequate. Exclusion criteria included central nervous system metastases, progression while on prior taxane chemotherapy, a disease-free interval less than 12 months since completion of any taxane-containing adjuvant therapy, pre-existing grade 3 or 4 neuropathy (NCI CTC), prior mitomycin C or cisplatin chemotherapy or a cumulative dose of more than 450 mg/m 2 of anthracyclines. All patients gave written informed consent. This study was approved by the Institutional Review Board of the Columbia Presbyterian Medical Center.
Patients with completely resected or irradiated metastases were eligible provided that their metastases were not previously refractory to chemotherapy. For patients with bone as the only site of metastases, radiographic evidence of tumor response (ie sclerosis of prior lytic lesions) coupled with symptomatic improvement and where applicable falling tumor markers were sufficient. Progression of disease between cycles, or life-threatening grade 4 toxicity resulted in removal from the study. Patients were evaluated by a reference neurologist and nerve conduction studies were performed at baseline and prior to the second highdose cycle.
Treatment
The treatment plan is outlined in Figure 1 . Induction chemotherapy was delivered by the referring oncologist. After documentation of at least a partial response in patients with measurable disease and after at least three cycles of chemotherapy in patients with completely resected or radiated disease, peripheral blood hematopoietic progenitors were mobilized with chemotherapy and G-CSF (5 g/kg/day subcutaneously) and a minimum of 3 ϫ 10 6
CD34
+ (CD45 + /CD14 Ϫ ) mononuclear cells per kilogram were harvested and cryopreserved using previously published standard techniques. were administered over 96 h on days Ϫ7 to Ϫ3. Mesna 7500 mg/m 2 (1500 gm/m 2 /day) was administered over 120 h. The remaining peripheral blood stem cells were infused on day 0. The concomitant use of steroids, barbiturates, acetaminophen during chemotherapy was prohibited to avoid affecting P450 drug metabolism.
All patients had complete blood counts and chemistries assessed daily. Prophylactic ciprofloxacin 500 mg twice a day, fluconazole and acyclovir (for HSV + patients) was begun when the ANC fell below 500/l. G-CSF (5 g/kg/day subcutaneously) was begun after each stem cell infusion and was continued until the ANC у1000/l for 2 consecutive days. After the first neutropenic fever, the Cipro was stopped and broad-spectrum antibiotics were instituted. Patients were transfused with irradiated (2500 rads) products for hemoglobin Ͻ8 gm/dl or platelets Ͻ20 000/l.
Post-intensification therapy:
Following recovery from three intensifications, sites of prior bulk disease were excised or irradiated when feasible. Patients with estrogen and/or progesterone receptor-positive tumors received antihormonal agents after completing high-dose therapy, when appropriate. Patients who previously received bisphosphonates were continued on this therapy also. If patients had previously received trastuzamab, they had the option to continue this therapy.
Definition of terms and response
Hematologic recovery was measured from day 0 to ANC у500/l, and a platelet count Ͼ20 000/l unsupported by transfusion. Tumors were assessed by physical examination and imaging studies at entry and 4 to 6 weeks after discharge from the hospital.
A complete (CR) or partial response (PR) is defined as the complete disappearance or у50% reduction in the sum of the products of the largest bi-perpendicular diameters of all measurable disease for at least 4 weeks. Partial response* (PR*) is the complete resolution of all soft tissue or visceral disease with sclerosis of prior lytic bone lesions. Stable disease is a Ͻ25% reduction in the bi-dimensional measurements of the lesions. Disease progression (POD) is an increase of 25% in the tumor size or the appearance of new lesions.
Statistical analysis
This was designed to have 90% power to detect a response rate of 70% vs an expected response rate of 50%, using a Simon design. Descriptive statistics are reported as medians. Disease-free survival and overall survival are defined as the time from discharge from hospital after intensification 3 until disease progression or death, respectively, and the curves were estimated by the Kaplan-Meier product limit method. 18 If the patient died prior to their discharge from the third cycle, inclusion in the survival analysis is as a toxic death.
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Results
Patient characteristics
From January 1997 until June 2000, 61 women entered this study. Patient characteristics are listed in Table 1 . The median age for all patients was 46 years with a range of 24 to 64 years of age.
Forty-two women were initially diagnosed with localized breast cancer. Primary invasive breast cancer was bilateral in four patients. Six patients had a history of stage 1, 30 stage II and 6 with stage III breast cancer. Ten patients were node negative at diagnosis, and 12 had у4 lymph nodes involved with breast cancer. Six patients had an ipsilateral breast tumor recurrence prior to their diagnosis of advanced breast cancer. Most patients received adjuvant chemotherapy (39) with 22 (56%) having received a doxorubicin-containing regimen and one also a taxane-containing adjuvant regimen.
Thirty-four patients had undergone a modified radical mastectomy, 20 a lumpectomy, axillary node dissection and breast radiation therapy. Eight patients had undergone chest wall radiation therapy as part of their primary therapy. The median disease-free interval from initial diagnosis of primary breast cancer to stage 4 disease was 47 months (range, 3-108 months).
Initial presentation of Stage IV breast cancer:
Nineteen patients (31%) had advanced breast cancer as their initial diagnosis. Predominant metastatic sites included bone (6), lymph nodes (5), lungs (4), liver (3), and chest wall (1). One patient had undergone tandem high-dose chemotherapy with stem cell support as initial treatment for her diagnosis of advanced breast cancer at another Institution with a disease-free interval of 6 years prior to her recurrence and subsequent entry onto this trial.
Induction therapy: The majority of patients had one prior regimen for metastatic breast cancer (range, 1-3). Patients received a median of six cycles of induction chemotherapy prior to the first intensification (range, 2-24 cycles). Ten patients underwent induction with a doxorubicin-based regimen, 26 with a taxane-based regimen, and 13 with both a doxorubicin-taxane combined regimen. After completion of induction, eight were in complete response and 30 in partial response. Sixteen patients had disease confined to bones and five had their only sites of disease resected after an initial PR to induction therapy and hence are inevaluable for treatment response to high-dose therapy. One patient had a complete resolution of soft tissue disease and had residual bone scan abnormalities (PR*).
Treatment
All toxicities are presented in Table 2 .
Intensification 1: Paclitaxel with peripheral blood stem cell support:
Sixty-one patients were treated with paclitaxel. Most patients were readmitted with neutropenia/fever (31%) and less frequently for severe mucositis/esophagitis (5%). Positive blood cultures were obtained in seven patients. Isolated species included Staphylococcus epidermidis (3), Staphylococcus hominis (2), Micrococcus (1), Proprionibacterium acnes (1) . Two patients developed supraventricular tachycardia with conversion to normal sinus rhythm with medical therapy. Neurotoxicity was predominantly sensory; however, motor weakness and autonomic symptoms were also observed in some patients. Both motor and sensory changes were reversible. Fourteen patients received glutamine in a second study to determine if symptoms of peripheral neuropathy could be ameliorated. 19 Myalgias required varying amounts of analgesia (acetominophen to morphine sulfate) and were observed in most patients. Constipation lasting up to 1 week was observed but no bowel obstruction occurred and this problem resolved with aggressive bowel regimens. Three patients died of toxicity (5%). One toxic death occurred at day +13 after the patient was discharged home after intensification 3. This patient's hospital course had been uncomplicated. A post-mortem was unrevealing and an arrhythmia is possible. The second toxic death was at day +56 after intensification #3. The cause was multifactorial including overwhelming sepsis from resistant Pseudomonas aeroginosa, and vancomycin-resistant Enterococcus faecalis with severe disseminated intravascu-153 Table 3 Tumor responses lar coagulation which resulted in persistant lower GI bleeding and an unrelated aneurysmal CNS bleed. The third toxic death at day +39 from acute respiratory distress syndrome following sepsis with resistant organisms including resistant Pseudomonas aeroginosa, and vancomycin-resistant Enterococcus faecalis. Hematologic: The median time to ANC у500/l and platelets to Ͼ20 000/l was similar to our phase I trial with a range from 6 to 10 days for ANC recovery and 13 days for platelet recovery. 16 
Treatment response
Of the 61 patients entered, 57 are available for evaluation. One patient refused to proceed past intensification 1, and three died of toxicity. Thus 57 patients are evaluable for time to progression and overall survival and are included in all analyses. The patient who did not proceed to intensification 2 and 3 is included in the toxicity analysis of intensification 1 only.
Of the 30 patients evaluable for response, 12 patients (40%) converted from a PR to a CR, nine converted to a PR* (30%), five additional patients (17%) had a further PR. The PR to CR/PR* conversion rate is 70% for an overall response rate of 87% (Table 3 and Figure 2) .
Three patients who presented with stage 4 disease underwent a mastectomy after completion of the high-dose chemotherapy. Two patients had residual microscopic invasive breast cancer and ductal carcinoma in situ and one had a pathologic complete response. 
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At a median follow-up of 31 months, the progressionfree survival is 30% (Figure 3 ). For those who achieved a complete response, 11 of 21 (52%) remain progressionfree. Seven of 12 (58%) patients who converted from a prehigh-dose chemotherapy PR to a CR are disease-free. Only one of the 10 patients with resolution of all soft tissue or visceral disease and persistently abnormal bone scans (PR*), is disease-free. The median disease-free interval for this group was 9 months (range 5-31 months). Two of 14 patients who had disease confined to their bones are disease free and two of the four patients who were stage 4 NED continue to be disease-free.
Discussion
Complete response after high-dose chemotherapy continues to be the most significant prognostic factor for prolonged disease-free survival according to the North American Autologous Bone Marrow Transplant Registry (NAABMTR) and multiple single institution trials. Strategies to increase the complete response rate include incorporation of new drugs on alternative schedules, the use of repetitive high-dose chemotherapy cycles and the use of novel post-consolidation strategies.
This study has adopted the strategy of repetitive dosing and the incorporation of new active agents. The advent of improved technology (peripheral blood stem cells and growth factors) has made this a feasible strategy because of accelerated marrow recovery. Paclitaxel has been escalated in combination with other chemotherapy agents and incorporated into other high-dose regimens. The dose-limiting toxicity observed in these combination chemotherapy studies were coma and an ARDS-like capillary leak syndrome at doses of 825 mg/m 2 . [20] [21] [22] [23] We observed dose-limiting but largely reversible peripheral neuropathy as a consequence of the high-dose paclitaxel. This neuropathy may be ameliorated with concurrent glutamine administration. 19 All intensifications were given on time and the side-effect profile was consistent with what has been reported in the literature from ours and other groups.
Several issues remain outstanding. First, is whether paclitaxel is the best agent to incorporate into this high-dose regimen. In this study at this dose and schedule, the com- plete response rate is quite high (70%). To date, none of the other new chemotherapeutic drugs active in breast cancer appear to be good candidates for dose escalation based on their toxicity profile in the conventional dose setting. When compared to our prior study of a dose escalation of paclitaxel (400-825 mg/m 2 ) there was no significant difference in the response rate or disease-free survival. However, the incidence of transient peripheral neuropathy was increased. The second issue is whether the paclitaxel should be combined with another agent that enhances the response rate without increasing toxicity. Flavopiridol, a cyclindependent kinase signal transduction inhibitor that may reverse drug resistance, may be a potential partner. 24 The issue of repetitive dosing bears further study if this approach is to be a component of an overall treatment strategy of women with advanced breast cancer. Put into context, a single high-dose cycle of chemotherapy with stem cell support for advanced breast cancer produces a response rate of 40%, the median disease free interval is 12 months and the 5-year disease interval is 15-20%. Tandem highdose cycles of chemotherapy with stem cell support appear to produce a higher response rate (60-85%) with a median disease-free interval of 24 months or greater depending on the number of cycles administered. Although these are indirect comparisons, it is certainly possible that in the short term an impact may be observed and may serve as an ideal platform for the addition of non-cytotoxic agents when minimal residual disease is the prerequisite for considering these varied agents. Immunotherapy approaches are being evaluated with mixed results to date. Certainly, this is a potential group that might benefit from other minimal residual disease approaches such as the addition of antisense compounds, anti-angiogenesis agents, and other biologics such as trastuzamab and VEGF-antibodies. Despite high response rates, the major challenge continues to be to maintain this response and represents a unique opportunity to evaluate minimal residual disease strategies in this population.
In conclusion, this study demonstrates the feasibility of administering three sequential high-dose cycles of chemotherapy in women with metastatic breast cancer responding to conventional dose chemotherapy. The toxic death rate is consistent with that reported in other high-dose studies in patients with metastatic breast cancer.
The larger issue is the role of high-dose chemotherapy in patients with advanced breast cancer. The first generation randomized studies of a single cycle of high-dose chemotherapy with stem cell support are now being reported and more than a dozen additional studies are underway. A few of these trials are evaluating multi-cycle high-dose chemotherapy vs standard chemotherapy, although the optimal multi-cycle high-dose regimen is yet to be established.
Given that the prognosis of metastatic breast cancer remains poor, many women may be willing to participate in studies intended to increase the proportion of patients who achieve CR and then to study new strategies aiming to eliminate occult residual disease.
